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ABSTRACT 
 
Toluene is a volatile solvent found in many household products and when intentionally 
inhaled results in intoxication. In rats, acute inhalation of toluene results in sedation and 
neurological impairments, with marked increases in ambulation and vertical behaviour 
during the recovery period. Previous in vitro research has shown that toluene may exert 
its effects by inhibiting NMDA receptors, and / or by activating GABAA receptors. To 
test whether modulation of these receptors are also implicated in the changes in motor 
behaviour and neurological impairments resulting from toluene vapour inhalation, rats 
were injected with the NMDA receptor co-agonist D-serine (1000 mg/kg i.p.), the 
GABAA antagonist picrotoxin (0.05 mg/kg i.p.), or saline, and then received whole-body 
exposures to either 15 or 30 min of an abuse-relevant concentration of toluene vapour (~ 
5000 ppm). Open field behaviours including locomotion, rearing, and grooming as well 
as neurological impairments were quantified before and after toluene vapour inhalation. 
The results indicate that D-serine increases the speed of recovery from ambulatory and 
neurological impairments following 30 min (but not 15 min) exposure to toluene, 
suggesting an important role for NMDA receptors in the behavioural impairments 
induced by prolonged toluene intoxication. In contrast, picrotoxin did not affect recovery 
from toluene intoxication, suggesting that GABAA receptors are not implicated in the 
effects of toluene vapor inhalation, at least at the dose of toluene and exposure durations 
tested.  
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ABBREVIATIONS 
 
ABD   agonist-binding domain 
AMPA   2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
ANOVA  analysis of variance 
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GABAB  GABAB receptor  
HR-MAS 1H-MRS high-resolution magic angle spinning proton magnetic response 
spectroscopy 
IC50   half maximal inhibitory concentration   
i.p.    intraperitoneal 
IPSC   inhibitory postsynaptic current 
MK801  Dizocilipine  
mPFC   medial prefrontal cortex 
NAA   N-acetyl-aspartate 
NAC   nucleus accumbens  
NMDA  N-Methyl-D-aspartic acid 
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PCP    phencyclidine  
PD   Parkinson’s Disease 
RRN   retrorubual nucleus 
THIP   4,5,6,7-tetrahyroisoxazolo[5,4-c] pyridin-3-ol 
VEP   visual-evoked potential 
vMPJ   ventral mesopontine junction 
6-OHDA  6-hydroxydopamine  
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CHAPTER 1 - INTRODUCTION 
 
1.1. Toluene use and abuse 
Inhalation of volatile solvents (“inhalants”) for recreational purposes is a 
worldwide phenomenon.  Solvents are inhaled to reach a high characterized by euphoria 
and are more commonly abused in adolescent populations living in isolated, remote and 
impoverished communities (Embleton, Mwangi, Vreeman, Ayuku, & Braitstein, 2013). 
Of the solvents commonly used for recreational purposes, most contain the aromatic 
hydrocarbon toluene (methyl benzene). Toluene is a volatile solvent found in common 
household products including paints, thinners, adhesives, lacquers, disinfectants and 
gasoline. Toluene is highly lipid soluble, giving it the ability to readily cross the blood 
brain barrier and making it particularly toxic for lipid rich tissues like the brain. Long-
term toluene abuse can lead to deficits in cognitive function, decreased intelligence 
scores, personality changes, gait/motor impairments and severe brain damage including 
significant white matter loss (Filley, Halliday, & Kleinschmidt-DeMasters, 2004; 
Fornazzari, Wilkinson, Kapur, & Carlen, 1983; Rosenberg et al., 1988). Acutely, toluene 
vapour inhalation results in robust motor and neurological impairments which have been 
studied in both humans and rodents. 
 There are several methods for inhaling solvents including sniffing (breathing in 
solvents directly from the container or a heated pan), bagging (filling a bag with liquid, 
holding the opening of the bag around the mouth and nose, and inhaling) and huffing 
(soaking a cloth and inhaling the liquid while covering the mouth and nose). A typical 
user will inhale for tens of minutes at a time, and inhale anywhere between 5000 and 15 
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000 parts per million (ppm) of solvent (Brouette & Anton, 2001; Marjot & McLeod, 
1989; Wilkins-Haug, 1997). Products containing volatile solvents are typically abused by 
young adolescents, which may be due to ease of availability and low cost. In a recent 
survey of Ontario students, inhalant use was highest in Grade 8 students and declined 
with age, contrary to all other drugs surveyed, where use increases with age (Boak, 
Hamilton, Adlaf, & Mann, 2013). The same survey also noted that although solvent abuse 
is on the decline, solvents are still more often used by students in grade 7-12 over the past 
year in comparison to salvia, OxyContin, synthetic cannabis and non-prescription use of 
“ADHD”-related medications (Boak, et al., 2013). The prevalence of toluene use may be 
even higher in school-aged children not currently attending a formal educational 
institution. 
Although solvent use occurs around the world and at a relatively high prevalence 
in some communities, our understanding of how these solvents affect the brain has lagged 
behind other recreational drugs. 
 
1.2. Toluene-induced behavioural impairments in humans 
Studies of the acute behavioural effects of toluene in humans are limited due to a 
lack of controlled manipulations and difficulty accessing populations of recently 
intoxicated users.  The studies conducted with human participants have shown that 
toluene intoxication is characterized by robust motor and neurological deficits. One such 
study looked at children recently hospitalized for glue sniffing and noted a series of 
impairments including staggering gait, dysarthria, nystagmus and intention tremors 
(King, 1982).  Similarly, adults pulled over while driving under the influence of toluene 
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had high blood toluene concentration levels and were exhibiting behavioural symptoms 
including slurred speech, staggering gait and appeared to be in a ‘twilight state’ in which 
actions were performed without conscious awareness and immediately forgotten (Capron 
& Logan, 2009).  Another study saw similar impairments in drivers which were 
characterized by the same ‘twilight state’ and staggering gait and slurred speech, although 
tremors were also evident (Miyazaki, Kojima, Yashiki, Chikasue, & Tsukue, 1990). 
Acute toluene-induced tremors are not active at rest, suggesting that the origin of these 
tremors may be caused by striatal, pyramidal or cerebellar dysfunction and appear to be 
similar to tremors produced by Parkinson’s disease (PD) (Miyagi, Shima, Ishido, 
Yasutake, & Kamikaseda, 1999). Chronic toluene abuse can lead to resting tremors, 
present even while the user is sober.  These tremors have been described as either 
postural tremors (tremors seen when an individual voluntarily holds a position against 
gravity, for example, when arms are outstretched), or intention tremors (tremors present 
during goal-directed movement). Along with tremors, other peripheral behavioural 
disruptions including myoclonus (the involuntary jerking of a muscle or muscle group) 
have been noted in long-term toluene users (Arai, Tokumaru, Yagishita, Hirayama, & 
Iwasaki, 1986; Sugiyama-Oishi et al., 2000). These behavioural manifestations are 
similar to levodopa-induced dyskinesia seen in PD patients.  Both PD dyskinesia and 
toluene-induced deficits resulting from cerebellar atrophy and decreased white matter in 
limbic structures were treated with amantadine (a non-selective NMDA receptor 
antagonist) suggesting that these behaviours may result from glutamatergic dysfunction 
(Deleu & Hanssens, 2000; Fox, 2013). 
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Neurological examinations have found robust neurological deficits in youth 
admitted to a substance abuse rehabilitation clinic, where more than half of the solvent 
users showed pathological findings in a variety of tests including a neurological 
assessment which measured pyramidal, peripheral and sensory nerve involvement (Uzun 
& Kendirli, 2005).  This study employed several techniques including; 
electroencephalography (EEG), nerve conduction studies and somatosensorial (SEP), 
visual (VEP) and brainstem auditory (BAEP) evoked potentials (Uzun & Kendirli, 2005).  
These findings may be the result of brain stem changes, as more participants showed 
changes in brain-stem evoked potentials compared to somatosensory evoked potentials 
(Uzun & Kendirli, 2005). In another study, adult long-term toluene users were rated 
based on performance in a neurological test battery and results showed that cranial nerves 
I, II and III were impaired in a significant number of users (speaking to decreased 
olfaction, optic atrophy and sensory-neural hearing loss) (Fornazzari, et al., 1983). These 
patients also exhibited cerebellar symptoms, and peripheral tactile deficits as evidenced 
by decreased distal touch sensation and decreased ankle jerk responses (Fornazzari, et al., 
1983). 
Taken together, it is clear that toluene use results in robust motor and neurological 
impairments, both acutely and over time, although these studies are limited due to lack of 
experimental manipulation. Therefore animal models of acute toluene intoxication have 
been developed to further understand these behavioural manifestations and their 
biological underpinnings.  
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1.3. Toluene-induced behavioural impairments in rodents 
Acute toluene exposure results in a series of behavioural impairments in rodents, 
but is most characterized by hyperlocomotion during the recovery period. Locomotor 
behaviour was not shown to be altered following 20 min exposure to 2000 or 8000 ppm 
toluene, while exposure to 4000 ppm toluene did increase locomotion, indicating a 
potential dose-response relationship between toluene and locomotor behaviour (Bowen, 
Charlesworth, Tokarz, Wright, & Wiley, 2007). Similarly, mice exposed to 30 min of 0, 
100, 2000, 8000 or 10 000 ppm toluene revealed increased locomotor activity when doses 
of toluene were < 8000 ppm, whereas following exposures ≥ 8000 ppm toluene, a 
biphasic response where locomotion was first increased and then followed by 
hypoactivity was noted (Batis, Hannigan, & Bowen, 2010). A comparison of adolescent 
and adult rats in a motor behavioural and neurological assessment assay showed that 
adolescent, young adult, adult and older adult rats all exhibit increased locomotion, 
impaired beam crossing, impaired gait and increased neurological impairments following 
an acute exposure to 15 min or 30 min of 5000 ppm toluene (Samuel-Herter, Slaght, & 
McKay, 2014). Following injection of 250-750 mg/kg (i.p.) toluene, rats exhibited 
hyperlocomotor behaviour and motor deficits in a rotarod task; the hyperlocomotion and 
motor coordination deficits were attenuated by the NMDA receptor co-agonist D-serine 
(Lo, Wu, Sue, & Chen, 2009). Rats injected with 600-1200 mg/kg (i.p.) toluene exhibited 
an inverted U-shape dose response curve to the locomotor stimulating effects of toluene, 
when behaviour was tested every 20 min for 3 hr following toluene injection, and these 
hyperlocomotive effects were blocked by the selective D2 dopamine antagonist 
remoxipride (Riegel & French, 1999). A 6-hydroxydopamine (6-OHDA) lesion of the 
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nucleus accumbens (NAC) or pre-treatment with the metabotropic mGlu2/3 receptor 
agonist LY379268 also attenuated toluene-induced increases in locomotion (Riegel, Ali, 
& French, 2003).  
Open field behaviours other than locomotion have also been quantified during and 
following toluene exposure and include findings of decreased rearing behaviour (Bowen, 
Batis, Paez-Martinez, & Cruz, 2006; Duncan et al., 2012; Tegeris & Balster, 1994).  
Decreased rearing behaviour following toluene inhalation may be the result of decreased 
balance and thus an inability to stand on the hind legs, as toluene-exposed animals do 
display difficulty in maintaining balance in balance beam and rotarod tasks (Chan, 
Chung, Stoker, Markou, & Chen, 2012; Chan, Lee, Lin, Wu, & Chen, 2012; Lo, et al., 
2009; Samuel-Herter, et al., 2014).  D-serine was able to attenuate the motor 
incoordination effects produced by toluene in a rota rod task suggesting that decreased 
balance behaviour may be the result of NMDA receptor hypo function (Lo, et al., 2009). 
Grooming behaviour also decreased following toluene exposure, which may be similarly 
affected by balance issues, or may indicate an anxiolytic effect of toluene (Samuel-
Herter, et al., 2014). Toluene has been shown to act as anxiolytic in rats, as exposure to 
1000-6000 ppm toluene increased time spent in the open arms of an elevated plus maze 
(Bowen, Wiley, & Balster, 1996). Similarly in mice, toluene dose-dependently (0, 1000, 
2000 or 4000 ppm toluene for 30 min) decreased measures of anxiety in both a burying 
behaviour and plus-maze task (Lopez-Rubalcava, Hen, & Cruz, 2000).   
The presence of stereotypic (repetitive) behaviours have also been identified 
including hindlimb myoclonus, (the rhythmic moving of the hind limb in a 
kicking/scratching motion) (Himnan, 1984). A neurological assessment battery 
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comparing the effects six alkylbenzenes on mice behaviour showed that 20 min exposure 
to between 2000 and 8000 ppm toluene decreased rearing, arousal, sensorimotor 
reactivity, mobility and increased gait abnormalities and clonic movements (Tegeris & 
Balster, 1994). Using an adapted neurological assessment battery, toluene has been 
shown to dose-dependently and age-dependently increase the presence of behaviours 
such as salivation, lacrimation, tremor and myoclonus either during exposure or during 
recovery following exposure to toluene (Samuel-Herter, et al., 2014). Salivation and 
lacrimation were only present within the exposure chamber, likely as a result of the 
irritant effects of toluene (Balster, 1987). 
The behavioural profiles of acute toluene exposure (including hyperactivity at low 
doses, decreased activity at high doses, tremor and myoclonus) are similar to other drugs 
including the NMDA receptor antagonist phencyclidine (PCP) and the GABA receptor 
agonist ethanol. These similarities have led to studies seeking to understand the 
pharmacological profile of acute toluene inhalation.  
 
1.4. The role of NMDA receptors in toluene intoxication  
1.4.1. Behavioural evidence 
Toluene produces a behavioural profile of effects similar to NMDA receptor 
antagonists that are characterized by hyperlocomotion, ataxia at higher doses, salivation, 
nystagmus and circling behaviour (Willetts, Rice, & Balster, 1990). These similarities are 
supported by the action of toluene as a partial substitute for PCP in a drug discrimination 
task where toluene dose-dependently acted as a partial substitute for mice trained to 
discriminate 2 mg/kg (i.p.) PCP (Bowen, Wiley, Jones, & Balster, 1999; Cruz, 
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Gauthereau, Camacho-Munoz, Lopez-Rubalcava, & Balster, 2003). As such, it is 
reasonable to suggest that toluene may exert its actions in a similar manner to NMDA 
antagonists like PCP.  Following a 30 min exposure to 4000 or 8000 ppm toluene, mice 
were given a seizure-inducing dose of NMDA and behaviour was measured (Cruz, et al., 
2003).  Toluene dose dependently reduced the occurrence of seizures, increased the 
latency to reach an occurrence of seizure, decreased NMDA-induced neurological 
impairments and protected against NMDA-induced lethality indicating a potential 
antagonist effect of toluene at the NMDA receptor (Cruz, et al., 2003). There is further 
evidence to suggest that toluene acts specifically to inhibit the NMDA receptor as steady 
state pattern-elicited visual-evoked potentials (VEPs) were blocked by injection of the 
NMDA antagonist MK801 prior to toluene inhalation, and VEPs were unaffected when 
MK801 was injected post-exposure to toluene (Bale et al., 2007). Further, it was recently 
shown that administration of the NMDA receptor co-agonist D-serine (1000 mg/kg, i.p.) 
prior to toluene injection (250-750 mg/kg, i.p.) resulted in a decrease in the motor 
incoordination, hyperactivity and memory impairments typically seen following acute 
toluene injections (Lo, et al., 2009).  There were some limitations to this study, including 
the difference between behaviour following injected and inhaled toluene, as well as the 
quantification of motor behaviour over 90 min of recovery.  It will be necessary to 
replicate this study using an inhalation paradigm, and investigate in more detail the 
effects of D-serine on behaviour. Similarities between toluene and NMDA antagonists 
have also been demonstrated by studies completed in vitro at the cellular level.   
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1.4.2. Evidence from cellular recording 
There is evidence to suggest that toluene does have direct effects on NMDA 
receptors. In Xenopus laevis oocytes, toluene dose-dependently and subunit-dependently 
inhibited recombinant NMDA receptors (Cruz, Mirshahi, Thomas, Balster, & Woodward, 
1998).  Specifically there was a high affinity for the NR1/2B subunit combination with an 
IC50 value for toluene-induced inhibition of 0.17 mM, while the NR1/2A and NR1/2C 
subunit combinations were 6 and 12 fold less sensitive respectively (Cruz, et al., 1998). 
Toluene did not significantly affect non-NMDA receptors indicating that toluene is 
specifically inhibiting ion channel gating, and not compromising the cell membrane as 
once postulated (Cruz, et al., 1998). In a whole cell patch clamp experiment of cultured 
hippocampal neurons, toluene dose-dependently inhibited NMDA receptor-mediated 
responses (with an IC50 of 1.5 mM) but did not affect AMPA or kainate receptor 
responses indicating specificity for NMDA receptors (Bale, Tu, Carpenter-Hyland, 
Chandler, & Woodward, 2005). Further, this study noted that prolonged toluene treatment 
(1 mM over 4 days) increased NR2A and NR2B, but not NR1, subunit expression, and 
this increased subunit expression led to greater whole-cell responses when NMDA was 
applied (Bale, et al., 2005). Although NR1 subunit levels were not increased following 
prolonged toluene exposure as measured by immunoblotting, an immunohistochemical 
analysis of cultured cells showed increased NR1 subunit density (Bale, et al., 2005). In a 
similar experiment looking at medial prefrontal cortex (mPFC) neurons, whole-cell patch 
clamp experiments showed that toluene dose-dependently (0.1 – 3 mM) inhibited 
NMDA-mediated excitatory post-synaptic currents (EPSCs) (Beckley & Woodward, 
2011). This effect was cannabinoid receptor 1 (CBR1) sensitive indicating a potential 
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effect of toluene on CBR1 receptors, although whether this effect is direct or not has yet 
to be determined (Beckley & Woodward, 2011). When toluene was injected at 0, 200, 
500 and 1000 mg/kg (i.p.) in neonatal rats from postnatal day (PN) 4 to PN 7, toluene 
dose-dependently decreased intracellular Ca2+ signals in response to exogenous 
glutamate/glycine and NMDA/glycine in cultured cerebellar granule cells (Chen, Wei, 
Lin, Chien, & Chan, 2005).  This effect was attributed to the NR2B subunit as toluene 
had no effect on the inhibition produced by Mg2+ or MK801 but did decrease the potency 
of the NR2B preferring antagonist, ifenprodil (Chen, et al., 2005). Following 10 days of 
exposure to 8000 ppm toluene for 30 min/day, a Western blot analysis showed that the 
expression of the NR1, NR2B and GluR2/3 subunits were all increased in the mPFC, 
while the NR1 subunit alone showed increased expression in the substantia nigra 
compacta, and the NR2B subunit alone showed increased expression in the nucleus 
accumbens (Williams, Stafford, & Steketee, 2005). This increase in subunit expression 
may drive changes in glutamate levels in the brain. 
 
1.4.3. Evidence from microdialysis and magnetic resonance spectroscopy 
In vivo microdialysis experiments showed that the extracellular glutamate levels 
in the hippocampus of freely moving mice were rapidly and reversibly increased within 
30 min following an acute injection of 150 or 300 mg/kg (i.p.) toluene, as measured by 
liquid chromatography (Win-Shwe et al., 2007). In a high-resolution magic angle 
spinning proton magnetic response spectroscopy (HR-MAS 1H-MRS) study, young adult 
rats were found to be the most sensitive to acute (2 x 15 min) exposure to 8000-12000 
ppm toluene as compared to adolescent and adult rats (O'Leary-Moore et al., 2009).  
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Toluene exposure resulted in decreases in choline and GABA levels in the frontal cortex 
and striatum and decreased glutamine and N-acetyl-aspartate (NAA) levels in the frontal 
cortex (O'Leary-Moore, et al., 2009).  
 
1.5. NMDA receptors and D-serine 
The above evidence suggests that toluene acts as an NMDA antagonist, similar to 
PCP.  The NMDA receptor complex is well-characterized as a glutamate-gated ion 
channel with a voltage-sensitive Mg2+ block.  D-serine has been identified as a potentially 
useful therapeutic for combating NMDAR hypo-function as it can be administered 
exogenously. In a clinical trial of patients with schizophrenia, D-serine (≥ 60 mg/kg/day) 
was an effective treatment for the persistent symptoms and neurocognitive dysfunction 
(Kantrowitz et al., 2010). 
Depletion of endogenous D-serine in serine-racemase knock-out mice led to 
behavioural changes including hyperlocomotion and increased anxiety (as measured by 
decreased exploration of the centre area in an open field task) (Basu et al., 2009). Studies 
have shown that the glycine site on NMDA receptors is not saturated in vivo, and that the 
introduction of exogenous co-agonists glycine or D-serine attenuated the 
hyperlocomotive behaviour caused by injection of MK 801 (0.2 mg/kg, i.p.) indicating a 
direct effect of glycine site activation on motor behaviour (Nilsson, Carlsson, & Carlsson, 
1997). D-serine injected intracerebroventricularly (1.0 μmol/rat) attenuated PCP and MK 
801 induced stereotypy and ataxia, indicating an ameliorative effect of D-serine on a 
variety of the behavioural effects of NMDA antagonists (Contreras, 1990). Further, MK 
801 induced stereotypy and ataxia were reduced in mice lacking in D-amino acid oxidase 
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(DAAO) activity indicating that increasing levels of endogenous D-serine by limiting the 
regulatory break-down enzymes may combat drug-induced NMDA receptor antagonism 
(Hashimoto, Oka, & Nishikawa, 1995). Exogenously injected D-serine has been targeted 
as a potential therapeutic for disorders characterized by NMDA receptor hypofunction, 
and has been shown to attenuate the hyperlocomotion, motor incoordination and memory 
deficits induced by toluene injection (Lo, et al., 2009).  Sarcosine (100 or 300 mg/kg, 
i.p.), an NMDA receptor co-agonist at the glycine site and a GlyT1 inhibitor, was shown 
to similarly reduce motor incoordination in a rota rod task, cognitive deficits in a novel 
object recognition task and toluene-induced hypothermia in mice (Chan, Chung, et al., 
2012). This evidence suggests that D-serine may act to attenuate the increased 
ambulatory behaviour and motor incoordination resulting from toluene intoxication, and 
as it attenuates stereotypic behaviour and ataxia caused by other NMDA antagonists 
including MK 801 and PCP.   
 
1.6. The role of GABA receptors in toluene intoxication  
1.6.1. Behavioural evidence 
The acute effects of toluene also share key similarities with the acute behavioural 
effects of ethanol including motor incoordination, hyperlocomotion at lower doses and 
decreased locomotion at higher doses.  Many of the effects of ethanol mirror those of 
GABAA receptor agonists, as a 15% solution of 95% ethanol (20 mL/kg, i.p.) induced 
effects such as sedation, which were attenuated by the GABAA receptor antagonist 
picrotoxin (Liljequist & Engel, 1982).  Toluene (300 – 5400 ppm) acted as a substitute 
for pentobarbital and ethanol (both substances known to activate GABA receptors) in 
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drug discrimination tasks (Rees, Coggeshall, & Balster, 1985; Rees, Knisely, Breen, & 
Balster, 1987). Toluene-induced prolongation of nystagmus (the result of a 30 min 
exposure to 1000 ppm toluene) following rotary acceleration was blocked by pre-
treatment of baclofen (1, 3 and 5 mg/kg i.m.) and 4,5,6,7-tetrahyroisoxazolo[5,4-c] 
pyridin-3-ol (THIP) (5, 10 and 15 mg/kg i.m.), a GABAB and GABAA agonist, 
respectively (Tham, Larsby, Eriksson, & Niklasson, 1990).  These results indicate that 
blocking GABA receptors blocks some of the effects of toluene. Additionally, toluene-
induced CPP (developed following 14 pairings of 30 min exposures to 3000 ppm toluene) 
was blocked by 150 mg/kg (i.p.) of gamma-vinyl GABA, suggesting a role of 
GABAergic transmission in the addictive potential of toluene (Lee, Schiffer, & Dewey, 
2004). 
 
1.6.2. Evidence from cellular recording  
Whole-cell patch clamp recordings from mPFC neurons revealed that toluene 
(0.3, 1 and 3 mM) enhanced stimulus-evoked GABA-mediated IPSCs; after TTX 
application, toluene continued to increase the amplitude and frequency of miniature 
IPSCs suggesting that the effects of toluene are action potential independent, and thus 
occur at the level of the synapse (Beckley & Woodward, 2011).  Cultured rat 
hippocampal neurons when subjected to prolonged toluene exposure (1 mM over 4 days), 
had reduced responses to exogenously applied GABA and reduced amounts of 
synaptically-activated GABA-mediated currents (Bale, et al., 2005). Another study using 
whole cell patch clamp recordings in hippocampal neurons found that GABA synapses in 
CA1 pyramidal cells were facilitated by 1 mM toluene (MacIver, 2009). Whole cell 
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voltage clamp studies looking at the effect of toluene on GABAA receptors expressed in 
human IMR-32 neuroblastoma cells showed that toluene (10 or 30 μM) inhibited GABAA 
receptors; this low concentrations of toluene is typical for occupational toluene exposure, 
but not the higher abuse-relevant concentrations of toluene (Meulenberg & Vijverberg, 
2003). Toluene-induced motor deficits may result from increased inhibitory synaptic 
transmission in the cerebellum, as toluene was recently shown to dose-dependently (0, 
0.1, 0.136, 1.0 and 3.16 mM) reduce the frequency of Purkinje cell action potential output 
in whole-cell patch clamp preparations (Gmaz & McKay, 2014). Toluene exposure for 10 
days (8000 ppm, 30 min/day) increased the GABAA α1 subunit in the mPFC and 
striatum, and decreased GABAA α1 subunit in the substantia nigra and VTA (Williams, et 
al., 2005).  This indicates that GABAA receptor subunit expression is particularly 
sensitive to toluene exposure and extracellular changes in GABA levels may be 
significantly affected by toluene exposure. 
 
1.6.3. Evidence from microdialysis and magnetic resonance spectroscopy 
In a rat microdialysis study, extracellular levels of GABA in the cerebellum were 
increased following toluene exposure (2000 ppm for 2 hr), and this effect was blocked by 
tetrodotoxin indicating the increase in extracellular GABA was sodium action potential 
dependent (Stengard, Tham, O'Connor, Hoglund, & Ungerstedt, 1993). In vivo 
microdialysis showed that following the same acute inhalation of toluene (2000 ppm for 2 
hr), extracellular GABA levels decreased in the globus pallidus during and after 
exposure, while striatal GABA levels increased post-exposure only (Stengard & 
O'Connor, 1994). HR-MAS 1H-MRS showed that acute exposure (2 x 15 min exposure 
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to 8000-12000 ppm) toluene reduced levels of GABA in the hippocampus (O'Leary-
Moore, et al., 2009).  
 
1.7. GABAA receptors and picrotoxin  
Toluene may act as a CNS depressant by increasing the activation of GABA 
receptors much like ethanol, and like ethanol, the behavioural impairments of toluene 
intoxication may be blocked or attenuated by GABAA receptor antagonists.  GABAA 
receptors are ligand-gated, ionotropic receptors found globally throughout the brain. They 
function as a binding site for the major inhibitory neurotransmitter GABA.  Influx of Cl- 
ions acts to hyperpolarize the postsynaptic neuron and thus results in an inhibitory 
response.  GABAA receptors with specific subunit combinations also allow for the 
binding of the allosteric modulating benzodiazepines at specific benzodiazepine binding 
sites.  
 Picrotoxin acts as a non-competitive channel blocker for the GABAA Cl
- channel 
and therefore acts to block inhibition in the postsynaptic cell (Carpenter, Lau, & 
Lightstone, 2013).  At a low dose, picrotoxin may block the behavioural effects of acute 
toluene inhalation as 0.5 mg/kg (i.p.) picrotoxin did not result in changes in baseline 
locomotion but did reduce ethanol-induced sedation by increasing locomotor activity 
when injected prior to ethanol injection (Liljequist & Engel, 1982). The possibility then 
emerges that picrotoxin may reduce the ataxic behaviour seen following exposures to 
toluene.  In contrast, systemic injections of picrotoxin at higher doses (1-4 mg/kg) 
resulted in increased masticatory movements, salivation, tremors and locomotion which 
are similar to the behavioural effects of toluene exposure indicating that picrotoxin may 
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act to worsen the behavioural impairments of toluene intoxication when used in higher 
concentrations (Chang, Wang, & Lin, 2004).  Picrotoxin counteracted chlordiazepoxide 
(a sedative drug and known benzodiazepine) induced decreases in rearing and locomotor 
behaviour but had no effect on chlordiazepoxide-induced decreases in head dipping, 
although picrotoxin significantly decreased rearing and locomotor behaviours when 
injected alone (File, 1982). Picrotoxin (1.0 mg/kg, i.p.) increased bouts of rearing but did 
not increase rearing duration, indicating that antagonizing the inhibitory actions of 
GABAA receptors may result in increased exploratory behaviour, and perhaps reduced 
anxiety (Garg, 1969). In contrast picrotoxin (0.6 and 1.0 mg/kg s.c.) proves to be 
anxiogenic, increasing corticosterone serum levels in mice and decreasing the amount of 
time spent in the open arms of an elevated plus maze (Stankevicius, Rodrigues-Costa, 
Camilo Florio, & Palermo-Neto, 2008). Therefore, lower doses of picrotoxin may 
decrease exploratory behaviour and reduce the anxiolytic effects of toluene.  Finally, 
following exposure to 5700 ppm toluene, animals showed increased AMPA/NMDA 
ratios at synapses of the mesolimbic core VTA dopamine neurons (similar to other 
abused drugs such as cocaine and may reflect initiation of long term potentiation (LTP)), 
and this effect was blocked by pretreatment with picrotoxin (Beckley & Woodward, 
2011). Although picrotoxin appears to have complex dose-dependent effects on 
behaviour, the balance of the evidence suggests that picrotoxin should attenuate the 
behavioural effects of toluene.  
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1.8. Hypothesis and aims  
Due to the similarities in behavioural effects of acute toluene intoxication in 
humans and rodents, a rodent model of toluene abuse will be employed to understand the 
potential underlying pharmacological roots of toluene-induced behavioural changes. This 
study aims to describe the effects of the NMDA receptor co-agonist D-serine on the well-
studied motor and neurological behavioural impairments induced by abuse-relevant 
concentrations of inhaled toluene.  Further, this study looks to explore the effects of the 
GABAA antagonist picrotoxin on toluene-induced behavioural impairments, as there is 
currently very little behavioural evidence that the motor and neurological impairments 
seen following acute toluene exposure are related to GABAergic transmission, although 
there is much cellular evidence to suggest that GABAA receptors are implicated in 
toluene intoxication.  Based on the similar behavioural outcomes between toluene and 
known NMDA receptor antagonists, and the behavioural similarities between toluene 
intoxication and select aspects of PD pathology, it is expected that D-serine will attenuate 
toluene-induced behavioural impairments. Based on the similarities between toluene 
intoxication and ethanol intoxication, it is postulated that the GABAA receptor antagonist 
picrotoxin will attenuate the motor and neurological deficits following acute toluene 
intoxication. 
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CHAPTER 2 - METHODOLOGY 
2.1. Animals 
Male Long-Evans rats (Charles River Laboratories, St-Constant, Quebec, ~ 3.5 
months old; n=44) were pair housed and maintained on a 12 hr light/dark cycle (lights on 
at 0700 hr) with food and water available ad libitum. Rats were allowed to acclimate to 
the facility for one week before handling.  Rats were handled for two days (~ 5 min per 
day) immediately prior to the onset of experiments. All experiments were approved by 
the Wilfrid Laurier University Animal Care Committee and were in accordance with the 
guidelines established by the Canadian Council on Animal Care. 
 
2.2. Drugs 
All drugs were purchased from Sigma-Aldrich (Oakville, ON) and administered 
intraperitoneally (i.p.).  D-serine was prepared at a concentration of 500 mg/mL in 
physiological saline and injected at a volume of 2 mL/kg (due to poor solubility in saline) 
for a final dose of 1000 mg/kg.  The D-serine solution was prepared daily; the solution 
was warmed and stirred to ensure complete dissolution and allowed to cool to room 
temperature prior to injection. Picrotoxin was prepared at a concentration of 0.5 mg/mL 
in physiological saline and injected at a volume of 1 mL/kg for a final dose of 0.5 mg/kg.  
The picrotoxin solution was warmed and stirred until completely dissolved and was 
refrigerated and stored in a tinfoil-covered bottle due to light sensitivity. The picrotoxin 
solution was warmed to room temperature prior to injection. Vehicle (0.9% saline, 
injected at 1 mL/kg) was similarly refrigerated and allowed to warm to room temperature 
prior to injection. 
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2.3. Apparatuses 
Rat behaviour was measured in a transparent, plastic open field environment (45 
cm by 30 cm by 34 cm; l x w x h) with a grid of six squares (15 cm by 15 cm) painted on 
the underside of the floor.  Mounted above the chamber was a web cam (Microsoft 
LifeCam HD 3000) which utilized Microsoft LifeCam.Ink software to record videos of 
each open field session for later quantification of behaviour. Videos were analyzed on 
Windows Media Player 2009.  Vapor exposure to either toluene (VWR; Mississauga, 
ON) or air took place in two, identical, custom-built, plastic chambers (~6 L in volume).  
Each exposure chamber was equipped with two 90 mL, fluid-filled, plastic reservoirs 
secured to opposite corners. In the ‘Toluene’ chamber, the reservoirs contained 20 mL 
each of liquid toluene, while in the ‘Control’ chamber the reservoirs contained 20 mL 
each of distilled water.  The reservoirs were equipped with plastic lids which had holes 
(~3 mm in diameter, covering ~30% of the lid surface) to allow for vapor release.  An 
external air source was connected to each reservoir via plastic tubing (0.25” inside 
diameter) and room air was pumped into each reservoir at a rate of ~600 mL/min.  In the 
‘Toluene’ chamber this rate of air-flow resulted in a toluene vapour concentration of 
~5000 ppm toluene (as measured in a previous study by gas chromatography (Perit et al., 
2012)). The concentration of 5000 ppm is a behaviourally relevant dose, as human 
inhalant users have been shown to inhale anywhere between 5000 and 15 000 ppm 
(Wilkins-Haug, 1997).  
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2.4. Open Field assessments  
Locomotion (defined as all four of a rat’s paws crossing a line in the open field 
environment), rearing (defined as the rat lifting both forepaws off the floor) and 
grooming (defined as bouts of activity where both forepaws were lifted and used to rub 
the face, or one hindpaw was used to scratch the side) were analyzed manually from the 
video recordings of each open field session.  
 
2.5. Neurological assessment  
The battery of tests selected for the neurological assessment had previously been 
used for the quantification of neurological impairments caused by toluene inhalation 
(Samuel-Herter, et al., 2014), and were based on a subset of tests from the SHIRPA 
(SmithKlein Beecham, Harwell, Imperial College, Royal London Hospital, phenotypic 
assessment) neurological test battery (Rogers et al., 2001). Tests were scored as follows: 
‘body position’ (0 = active, 1 = not active, where rats that exhibited active body position 
displayed movement and normal posture), ‘tremor’ (0 = not active, 1 = active, where 
tremors were typically present in the upper torso), ‘eyes’ (0 = open, 1 = closed), 
‘lacrimation’ (0 = absent, 1 = present, where rats eyes watered, or tears were noted in the 
fur directly below the eye), ‘startle’ (0 = present, 0.5 = barely present, 1 = absent, where 
rats positive for startling behaviour responded to a loud, unprimed auditory stimulus), 
‘salivating’ (0 = absent, 1 = present) and ‘myoclonus’ (0 = absent, 1 = present, where rats 
positive for myoclonus exhibited involuntary, repetitive, tic-like motions with any leg). 
All assessments were scored in real time while the animal was in the open field 
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environment. A ‘total neurological score’ was computed as the sum of all individual 
neurological behaviour scores.  
 
2.6. Experimental design  
Rats received the following four treatments in a randomized order: saline injection 
followed by air exposure (saline + air), saline injection followed by toluene exposure 
(saline + toluene), drug injection (D-serine or picrotoxin) followed by air exposure (D-
serine + air; picrotoxin + air), and drug injection (D-serine or picrotoxin) followed by 
toluene exposure (D-serine + toluene; picrotoxin + toluene). These treatments were 
administered on alternating days. Rats were also exposed to toluene for either a duration 
of 15 min or 30 min in order to examine the effects of toluene at different time points in 
the exposure paradigm. Previously it was shown that the 15 min exposure to 5000 ppm 
toluene resulted in increased activity immediately following exposure, while the 30 min 
exposure resulted in a period of ataxia followed by increases in behaviour, modelling a 
low and high dose respectively (Samuel-Herter, Slaght and McKay, 2014). Rats in the D-
serine experiment (n = 20 total; n = 10 for 15 min vapor exposures, n = 10 for 30 min 
exposures) were not used in the picrotoxin experiment (n = 24 total; n = 12 for 15 min 
vapor exposures, n = 12 for 30 min vapor exposures); rats used in 15 min vapor exposure 
experiments were not used in 30 min vapor exposure experiments.  
After injection with D-serine, picrotoxin or saline (see Figure 2.1) rats were 
placed in the centre of the open field environment and monitored for 10 min (“pretest”; 
divided into two 5 min blocks). Rats were then immediately placed in either the toluene 
or air exposure chambers and monitored for 15 or 30 min (“exposure”). Open-field 
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behaviours were not recorded or quantified inside the vapor exposure chamber due to its 
small size which restricted rat movement. Rats were then immediately removed from the 
exposure chamber and placed back into the cleaned open field environment (“test”) and 
monitored 30 min (divided into six 5 min blocks).   
 
 
 
 
Figure 2.1.  Timing of D-serine or picrotoxin injections. Figure additionally illustrates the 
timing of pretest, exposure, and test epochs. A) refers to the D-serine experiment, B) 
refers to the picrotoxin experiment.  
 
2.7. Statistics  
All data were analyzed using PASW Statistics 21 (SPSS Inc. Chicago, IL). D-
serine and picrotoxin experiments were analyzed separately. Total neurological score 
(and each of its components), locomotion, rearing and grooming were all analyzed 
separately. Each behaviour was initially analyzed using a repeated measures multivariate 
analysis of variance with one within subjects factor (trials: eight 5 min blocks 
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representing two 5 min blocks during the pre-test and six 5 min blocks in the test-phase) 
and three between subjects factors (drug: D-serine or picrotoxin vs. saline; vapor 
exposure: toluene vs. air; exposure duration: 15 min vs. 30 min).  Post hoc analyses were 
completed with one-way analyses of variance (ANOVAs) and paired t-tests, where 
appropriate. Statistical significance was set at p < 0.05. 
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CHAPTER 3 - RESULTS 
3.1. Toluene and NMDA Receptors (D-serine) 
Neurological score, ambulatory activity, vertical exploration and grooming 
behaviour were analyzed using an 8 x 2 x 2 x 2 four-way repeated measures analysis of 
variance with one level repeated (Trial) and three levels not repeated (Exposure: toluene 
vapour or air; Injection: D-serine or saline; Exposure Duration: 15 or 30 min).  Within 
subjects results are shown in Table 3.1 and between subjects results are shown in Table 
3.2. 
 
Table 3.1. Within subjects statistical results for the D-serine experiment 
 
Degrees of 
Freedom 
Neurological 
Score 
Ambulatory 
Behaviour 
Vertical 
Exploration 
Grooming 
Behaviour 
Trial 7,504 158.2*** 13.4*** 9.2** 39.2*** 
Trial x 
Exposure 
7,504 165.1*** 30.2*** 107.4*** 8.6** 
Trial x 
Injection 
7,504 4.2*** 3.9*** 1.5 3.2 
Trial x 
Exposure 
Duration 
7,504 7.7*** 45.9*** 168.2*** 6.4* 
Trial x 
Exposure x 
7,504 3.0** 4.0*** 5.0* 0.0 
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*p < 0.05, **p<0.01, ***p<0.001. 
 
 
 
Table 3.2. Between subjects statistical results for the D-serine experiment.  
Injection 
Trial x 
Exposure x 
Exposure 
Duration 
7,504 4.4*** 38.1*** 111.6*** 0.0 
Trial x 
Injection x 
Exposure 
Duration 
7,504 6.8*** 5.2*** 2.3 3.9 
Trial x 
Exposure x 
Injection x 
Exposure 
Duration 
7,504 4.0*** 5.2** 6.5* 1.4 
 
Degrees of 
Freedom 
Neurological 
Score 
Ambulatory 
Behaviour 
Vertical 
Exploration 
Grooming 
Behaviour 
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*p < 0.05, **p<0.01, ***p<0.001. 
 
Exposure 
 
1,72 
 
 
522.3*** 
 
177.2*** 7.8** 1.4 
Injection 
1,72 
 
9.0** 3.4 12.3** 0.1 
Exposure 
Duration 
1,72 
 
36.9*** 6.8* 25.2*** 2.8 
Exposure x 
Injection 
1,72 
 
3.1 0.8 0.4 0.0 
Exposure x 
Exposure 
Duration 
1,72 
 
19.2*** 23.1*** 12.4** 1.4 
Injection x 
Exposure 
Duration 
1,72 
 
1.3 0.0 0.0 0.6 
Injection x 
Exposure x 
Exposure 
Duration 
1,72 
 
0.1 0.0 0.8 2.3 
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3.1.1. Neurological Assessment 
Toluene exposure impaired neurological function as indicated by increased scores 
on the neurological assessment test battery, similar to previous findings (Samuel-Herter, 
et al., 2014).   There was a significant Trial by Exposure by Injection by Exposure 
Duration interaction (Table 3.1).  Injection of D-serine for the 15 min toluene exposure 
duration resulted in decreased peak impairment scores in comparison to the saline 
injected/toluene exposed group (Figure 3.1A); for the 30 min toluene exposure duration, 
D-serine injection significantly speeded up the recovery of neurological function (Figure 
3.1B).  When examining the individual components of the neurological assessment test 
battery, it was apparent that D-serine significantly facilitated the recovery of primarily 
tremor and myoclonus following the 30 min exposure duration (Figure 3.2). 
 
3.1.2. Locomotion  
Similar to the neurological assessment, amount of line crossing also resulted in a 
Trial by Exposure by Injection by Exposure Duration interaction (Table 3.1). This 
interaction was characterized by exposure duration differences where rats exhibited 
hyperlocomotive behaviour immediately following the 15 min exposure to toluene 
vapour, but following the 30 min exposure to toluene vapour, exhibited a period of ataxia 
followed by hyperlocomotion (Figure 3.1C and Figure 3.1D, respectively). D-serine 
reduced the latency for ambulation to return to baseline scores following toluene 
exposure, and this effect was exacerbated following the 30 min exposure duration in 
comparison to the 15 min exposure duration. 
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3.1.3. Rearing 
Exposure to toluene vapor (either 15 or 30 min) decreased rearing behaviour 
during the test phase. The interaction between Trial and Injection was revealed by post 
hoc analyses to be due to pre-test differences (Table 3.1). The effect of Exposure 
Duration by Trial also showed pre-test differences, with rats about to receive a 30 min 
exposure to toluene exhibiting fewer bouts of rearing.  During the test phase, the 15 min 
exposure group (Figure 3.1E) reared more than the 30 min exposure group (Figure 3.1F). 
 
3.1.4. Grooming 
There were no main effects of Injection, but there was an interaction between 
Trial and Exposure and between Exposure and Exposure Duration (Table 3.1).  
Following the 15 min exposure duration, toluene exposed rats groomed less while D-
serine + air rats showed increased grooming behaviour initially during the test phase, and 
saline + toluene rats groomed the most at the end of the test phase  (Figure 3.1G). 
Following the 30 min exposure duration, toluene-exposed rats groomed less in the first 
test phase time interval 0-5 min (Figure 3.1H).  
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Figure 3.1. Neurological assessment and open field measures for toluene-exposed, D-
serine treated, rats. Neurological assessment score (A, B), number of line crosses (C, D), 
number of bouts of rearing (E, F) and number of bouts of grooming (G, H) in an open 
field environment following either 15 (A, C, E, G) or 30 (B, D, F, H) min exposure to 
toluene vapour. * p < .05 toluene versus control. # p < .05 D-serine + toluene versus 
saline + toluene.  
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Figure 3.2. Tremor and myoclonus in toluene-exposed, D-serine-treated, rats. Presence 
or absence of tremor (A, B) and presence or absence of myoclonus (C, D) following 
either a 15 (A, C) or 30 (B, D) min exposure to toluene.  * p < .05 toluene versus control.  
# p < .05 D-serine + toluene versus saline + toluene. 
 
3.2. Toluene and GABAA Receptors (Picrotoxin) 
 Neurological score, ambulatory activity, vertical exploration and grooming 
behaviour were scored using an 8 x 2 x 2 x 2 four-way repeated measures analysis of 
variance with one level repeated (Trial) and three levels not repeated (Exposure: toluene 
vapor or air; Injection: picrotoxin or saline; Exposure Duration: 15 or 30 min).  Within 
subjects results are shown in Table 3.3, and between subjects results are shown in Table 
3.4. 
 
Table 3.3. Within subjects statistical results for the picrotoxin experiment.  
 
Degrees of 
Freedom 
Neurological 
Score 
Ambulatory 
Behaviour 
Vertical 
Exploration 
Grooming 
Behaviour 
Trial 7,616 182.7*** 61.7*** 245.2*** 10.7*** 
Trial x 
Exposure 
7,616 187.2*** 67.6*** 52.2*** 8.9*** 
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*p < 0.05, **p<0.01, ***p<0.001. 
Trial x 
Injection 
7,616 1.1 0.2 1.8 0.3 
Trial x 
Exposure 
Duration 
7,616 3.0** 15.2*** 0.8 0.7 
Trial x 
Exposure x 
Injection 
7,616 1.2 0.5 1.6 1.0 
Trial x 
Exposure x 
Exposure 
Duration 
7,616 2.4 14.8*** 1.8 0.6 
Trial x 
Injection x 
Exposure 
Duration 
7,616 0.9 0.3 1.0 0.9 
Trial x 
Exposure x 
Injection x 
Exposure 
Duration 
7,616 0.7 0.3 0.8 1.0 
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Table 3.4. Between subjects statistical results for the picrotoxin experiment.  
 
 
Degrees of 
Freedom 
Neurological 
Score 
Ambulatory 
Behaviour 
Vertical 
Exploration 
Grooming 
Behaviour 
Exposure 1,88 
 
511.8*** 
 
177.4*** 20.0*** 7.7** 
Injection 1,88 0.8 0.2 0.7 2.2 
Exposure 
Duration 
1,88 1.6 15.4** 0.0 0.8 
Exposure x 
Injection 
1,88 0.3 0.3 1.6 2.2 
Exposure x 
Exposure 
Duration 
1,88 2.7 7.2** 4.3* 2.9 
Injection x 
Exposure 
Duration 
1,88 1.3 1.3 0.0 0.4 
Injection x 
Exposure x 
1,88 0.0 0.4 0.4 0.2 
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*p < 0.05, **p<0.01, ***p<0.001. 
 
 
3.2.1. Neurological Assessment 
Toluene vapor exposure, either 15 or 30 min in duration, resulted in significant 
impairments as indicated by increased neurological assessment scores. Following the 15 
min exposure, peak neurological score and recovery to baseline was similar for both 
toluene exposed groups (Figure 3.3A). Pre-planned comparisons looked at differences 
between specific behaviours within the test battery including tremor and myoclonus.  
Rats exposed to toluene for 15 min trembled significantly more following exposure 
compared to air-exposed rats, and at the 15-20 min test phase interval, the groups 
exposed to toluene differed with the picrotoxin injected group trembling significantly less 
than the saline injected group indicating a potential effect of picrotoxin to  decrease the 
latency to return to baseline trembling scores (Figure 3.4A). Toluene exposed rats also 
showed differences in recovery from myoclonus where the saline injected rats displayed 
myoclonic behaviour longer than picrotoxin injected rats (Figure 3.4C). Immediately 
following the 30 min exposure duration, the picrotoxin + toluene group had neurological 
assessment scores higher than all other groups, and both toluene-exposed groups 
recovered to baseline in a similar fashion (Figure 3.3B). The neurological impairments 
driving this effect were tremor and myoclonus.  Trembling behaviour was increased in 
Exposure 
Duration 
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toluene-exposed animals, and persisted until the 5-10 min post-test interval (Figure 3.4B). 
Toluene-exposed animals also exhibited myoclonic behaviours more than controls 
(Figure 3.4D). At the 15-20 min test phase interval, the saline + toluene-exposed rats 
displayed myoclonic behaviour more frequently than the picrotoxin + toluene group 
indicating a potential effect of picrotoxin at this time point (Figure 3.4D). 
 
3.2.2. Locomotion 
Exposure to 15 and 30 min of toluene vapor resulted in impaired locomotor 
behaviour as compared to air-exposed controls.  Following the 15 min exposure, both 
toluene exposed groups were similarly impaired and recovered at the same rate with all 
groups ambulating more than the picrotoxin injected, air exposed group during test-phase 
interval (20-25) and the saline injected, toluene exposed group ambulating significantly 
more than all other groups during the last test phase interval (25-30 min) (Figure 3.3C).  
Following the 30 min exposure, there was no effect of picrotoxin as both the toluene 
exposed rats had similar scores on the number of line crosses and recovered to baseline at 
the same time (Figure 3.3D). 
 
3.2.3. Rearing 
Following the 15 and 30 min exposures to toluene, rearing was significantly 
decreased in toluene-exposed rats.  Air-exposed control rats showed differences in 
rearing following the 15 min exposure in which picrotoxin injected animals reared 
significantly less, which indicates a potential effect of picrotoxin on decreasing vertical 
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behaviour (Figure 3.3E).  Similarly, air control rats showed differences in rearing in the 
test phase following the 30 min exposure (Figure 3.3F).  
   
3.2.4. Grooming 
Grooming was initially decreased following both the 15 and 30 min exposure for 
toluene-exposed rats.  Following the 15 min exposure, the air exposed animals differed 
such that the picrotoxin injected group groomed more than the saline injected group. The 
picrotoxin injected, toluene exposed group groomed more than all other groups at post-
test interval (20-25) (Figure 3.3G).  Following the 30 min exposure, there were again 
differences between the air exposed groups indicating an effect of picrotoxin for 
increasing grooming behaviour (Figure 3.3H).   
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Figure 3.3. Neurological assessment and open field measures for toluene-exposed, 
picrotoxin-treated, rats. Neurological assessment score (A, B), number of line crosses (C, 
D), number of bouts of rearing (E, F) and number of bouts of grooming (G, H) in an open 
field environment following either 15 (A, C, E, G) or 30 (B, D, F, H) min exposure to 
toluene vapour. * p < .05 toluene versus control. # p < .05 D-serine + toluene versus 
saline + toluene. 
 
 
 
 
Figure 3.4. Tremor and myoclonus in toluene-exposed, picrotoxin-treated, rats. Presence 
or absence of tremor (A, B) and presence or absence of myoclonus (C,D) following either 
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a 15 (A, C) or 30 (B, D) min exposure to toluene.  . * p < .05 toluene versus control.  # p 
< .05 D-serine + toluene versus saline + toluene 
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CHAPTER 4 - DISCUSSION 
4.1. Overview 
The present study sought to quantify the behavioural effects of pre-treatment of 
the NMDA receptor co-agonist D-serine on an acute exposure to inhaled toluene. Further, 
the current study attempted to understand the role of GABAA receptors in toluene-
induced behavioural impairments by blocking GABAA receptor activation with the Cl
- 
channel blocker picrotoxin. Toluene (~5000 ppm) exposures lasting either 15 or 30 min 
resulted in robust neurological, locomotor, rearing and grooming impairments as seen 
previously (Samuel-Herter, et al., 2014). Pre-treatment of D-serine (1000 mg/kg) reduced 
the time to recover from toluene-induced hyperlocomotion and neurological impairments 
(tremor and myoclonus). Rearing behaviour was not an accurate measure of the effects of 
D-serine as there were pre-test differences between the groups, and grooming behaviour 
was not significantly affected by pre-treatment of D-serine. Pre-treatment of picrotoxin 
did not significantly affect recovery from acute toluene intoxication. This result indicates 
that the GABAA receptor is not implicated in the behavioural effects of the dose and 
duration of toluene, and dose of picrotoxin, used in the current study, indicating that 
GABAA receptors may be employed for different behavioural measures or at different 
toluene vapor doses. 
 
4.2. A potential mechanism through which toluene alters locomotor behaviour  
 Locomotor behaviour has been used as a measure of excitability and may reflect 
drug reward processes, as increased dopamine release in the NAC has been associated 
with the locomotor stimulating and rewarding properties of abused drugs.  One potential 
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pathway through which toluene may increase motor behaviour is through the blockade of 
NMDA receptors on GABA interneurons in the VTA, which could lead to enhanced 
dopamine cell firing via disinhibition (Riegel, Zapata, Shippenberg, & French, 2007) . 
However, blockade of GABAA receptors by picrotoxin did not affect motor behaviour in 
our study indicating a potentially different mechanism. Interestingly, NMDA antagonists 
such as PCP and MK 801 have been shown to induce hyperlocomotor behaviour in 
dopamine deficient (DD) mice, while restoring dopamine signalling in DD mice also 
increased locomotor behaviour indicating an independent, as well as synergistic effect of 
NMDA and dopamine transmission on locomotion (Chartoff, Heusner, & Palmiter, 
2005). In contrast, evidence suggests that toluene-induced changes in locomotion are 
dependent on dopamine transmission as the locomotor enhancing effects of injected 
toluene can be blocked by SCH23390, remoxipride, raclopride and nafadotride (D1, D2, 
D2 and D3 receptor antagonists, respectively) which may indicate a difference between 
toluene and other known NMDA antagonists (Lo, et al., 2009; Riegel & French, 1999). 
Inhaled toluene results in increased burst firing in dopaminergic cells of the VTA which 
is similar to the bursting pattern seen following glutamatergic activation of VTA efferents 
as measured by single-cell recording in anesthetized rats (Riegel & French, 1999). The 
use of ketamine (also a NMDA antagonist) as an anesthetic may have played a role in this 
change.  
The evidence suggests that toluene acts as an NMDA antagonist, similar to PCP.  
The NMDA receptor complex is well characterized as a glutamate-gated ion channel with 
a voltage sensitive Mg2+ block.  There are seven known NMDAR subunits (GluN1, 
GluN2A – GluN2D, GluN3A and GluN3B) which assemble into various heteromers.  It 
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has been shown that NMDAR inhibition by toluene is subunit specific, with NMDA 
receptors composed of the NR1/2B subunits being the most sensitive to toluene (Cruz, et 
al., 1998). In the adult forebrain, this receptor combination is found predominantly in 
peri- and extrasynaptic sites, and the presence of the NR2B subunit makes the NMDAR 
particularly mobile in cultured cells further complicating understanding the potential site 
of action of toluene (Paoletti, Bellone, & Zhou, 2013). All subunits are made up of 4 
domains including the agonist-binding domain (ABD) which binds co-agonists glycine 
and D-serine in subunits GluN1 and GluN3, and glutamate in GluN2 (Paoletti, et al., 
2013). As D-serine did not block the effects of toluene, as it only shifted the timing of the 
recovery from acute toluene intoxication, we can assume that there are other actions 
involved in the effects of toluene beyond NMDA receptor antagonism. 
 
4.3. D-serine and recovery from toluene intoxication  
Acute toluene exposure to either inhaled or injected toluene results in robust 
changes in locomotor behaviour which are biphasic. At low doses acute toluene exposure 
results in increased ambulation, while at high doses toluene exposure results in ataxic 
behaviour followed by hyperlocomotion during the recovery phase (Himnan, 1984; 
Samuel-Herter, et al., 2014).  As the longer duration exposure was more significantly 
affected by pre-treatment with D-serine, it may be the case that NMDA receptors are only 
affected when brain/toluene concentrations are higher or have been elevated for a 
prolonged period. The current study found that toluene acts like an NMDA receptor 
antagonist at concentrations high enough to produce ataxia followed by hyperlocomotion.  
The result of a study using the HR-MAS 1HR MRS technique to quantify 
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neurotransmitter levels following an acute binge-like exposure pattern (2 x 15 min 
exposures separated by 2 hr) found that glutamate levels were only decreased in the 
anterior striatum following the highest toluene vapor exposure (12 000 ppm) (O'Leary-
Moore, et al., 2009). This result indicates that toluene vapor may only affect 
glutamatergic output when brain/toluene concentrations reach a certain threshold. Due to 
dosing differences it is difficult to pinpoint exactly at what brain concentration this 
threshold may be reached.   
D-serine pretreatment also reduced the latency of recovery from specific 
neurological impairments resulting from toluene exposure, including myoclonus and 
tremor. Although in the current study picrotoxin had no effect on myoclonic behaviour, 
hindlimb myoclonus can be induced by picrotoxin injections (0.5 – 1.5 μg in 2 μL saline) 
in the caudate nucleus (Tarsy, Pycock, Meldrum, & Marsden, 1978). The onset of 
myoclonic behaviour was delayed in this study by pre-treatment of scopolamine (a 
competitive antagonist of the muscarinic acetylcholine receptor) (Tarsy, et al., 1978). 
Tarsy and colleagues therefore noted a shift in onset of myoclonic behaviour in the 
direction opposite of D-serine’s effect on toluene-induced hindlimb myoclonus noted in 
the current study. Myoclonic behaviour can also be blocked by NMDA receptor 
antagonists including MK 801 and S-ketamine when hindlimb myoclonic seizures are 
induced by opioids (Kolesnikov, Jain, Wilson, & Pasternak, 1997). These results together 
indicate that myoclonic behaviour is complex, and exhibited for a variety of reasons 
making it difficult to compare and explain the results reported in the thesis. However, it is 
clear that toluene produces a robust alteration in this behaviour as it has been observed 
and characterized in great detail (Himnan, 1984; Hinman, 1987). A potential cause of this 
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behaviour is alterations in brain stem function, as NMDA lesions (0.5 M, 0.5 μl) to the 
retrorubual nucleus (RRN) and ventral mesopontine junction (vMPJ) in cats resulted in 
hindlimb myoclonic behaviour (Lai & Siegel, 1997). As toluene produces high c-Fos 
activation in brainstem structures following 30 min exposures to 5000 ppm toluene (Perit, 
et al., 2012) it is reasonable to suggest that in the current study the effects of toluene in 
the brainstem may be responsible for the presence of myoclonic behaviour 
Toluene inhalation was also shown to induce tremors, and the recovery from 
trembling behaviour was increased by D-serine pre-treatment. As the cerebellum is a 
critical structure involved in motor timing, it is a major contributor to tremor pathology. 
A potential underlying cause of toluene-induced trembling behaviour is cereballar 
dysfunction. In a whole-cell patch clamp preparation, toluene was shown to enhance 
inhibitory drive on Purkinje cells (Gmaz & McKay, 2014). Alterations in Purkinje cell 
function have been linked to trembling behaviour in clinical populations (Axelrad et al., 
2008). Experimentally when Purkinje cell function was decreased by a knockout of 
sodium channel Nav1.6, mice displayed motor impairments similar to those seen 
following acute toluene inhalation including splayed gait and tremors during movement 
(Levin et al., 2006; Samuel-Herter, et al., 2014). Importantly, D-serine is found in the 
molecular layer of the cerebellum of mature rats, which houses the dendritic trees of 
Purkinje cells (Schell, Molliver, & Snyder, 1995). Specifically, motor coordination in a 
rotarod test was disrupted when the D-serine binding site of the GluD2 receptor was 
altered, providing a mechanistic link between the presence and proper function of D-
serine with motor coordination (Kakegawa et al., 2011). 
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4.4. Pharmacokinetics of toluene vapor inhalation and D-serine effects  
It was shown that log blood and brain toluene concentrations have a linear 
relationship with log air toluene concentrations (up to a 3 h exposure to 1000 ppm 
toluene) with a ratio of brain to blood toluene levels of 1.56 (Benignus, Muller, Barton, & 
Bittikofer, 1984). Similarly, a test of the CNS effects of differing toluene vapor 
concentrations and exposure durations was quantified using a signalled bar-press shock-
avoidance task (Kishi, Harabuchi, Ikeda, Yokota, & Miyake, 1988). It was found that 
blood and brain concentrations of toluene were closely linked to toluene vapor exposure 
concentration and duration, indicating that anything which may alter toluene absorption 
or excretion may shift behavioural outcomes.  Interestingly, it has been shown that blood 
concentrations of toluene do not increase in a linear fashion. In a recent study, 10 min 
exposures to 1000 – 6000 ppm toluene produce blood concentrations of toluene which 
were between 64% and 81% of those seen following 20 min exposures, indicating a 
potential saturation point (Shelton & Slavova-Hernandez, 2009). The current study used 
an exposure paradigm closely related to Shelton and Slavova-Hernandez. Therefore it is 
likely that there are considerable differences in the blood concentrations of toluene 
between the 15 and 30 min exposure group, which may also be a predictor of differences 
in brain/toluene concentrations.  
Toluene can be inhaled, consumed orally, injected or absorbed through the skin. 
For the purpose of the current study, we will focus on the pharmacokinetic processes as 
they relate to inhaled toluene.  The typical trajectory for inhaled substances is as follows: 
a) inhaled substances are absorbed in the lungs and enter the pulmonary arteries via gas 
exchange b) blood travels to the heart and the inhaled substance is pumped systemically 
46 
 
throughout the body (with a high proportion of blood travelling to the brain) c) tissues 
receive the blood, the inhaled substance is metabolized and waste is diffused back into 
the blood stream d) venous blood returns to the lungs and waste products are expelled via 
respiration, or metabolites are excreted in urine. Toluene tends to settle in lipid-rich 
tissues such as bone marrow, kidney, liver and the brain (Barceloux, 2012). Within these 
tissues toluene is metabolized primarily by cytochrome P450 isoenzymes to become 
benzyl alcohol (Gillette, 1959). Benzyl alcohol is then oxidised by alcohol and aldehyde 
dehydrogenases to become benzaldehyde and benzoic acid (Lof et al., 1993). 
Approximately 80% of inhaled toluene is excreted as hippuric acid (which is formed by 
conjugation of acid by glycine) (Lof, et al., 1993). A very small proportion (<1%) of 
metabolised toluene is excreted as o- and p-cresol, while 7-14% of toluene is excreted by 
exhalation (Lof, et al., 1993). 
 
4.4.1. Increased ventilation rates may drive D-serine-mediated increases in toluene 
vapor clearance  
As the results here indicate that D-serine acted to shift the recovery time for an 
acute toluene exposure as opposed to simply reducing the effects of toluene, it may be the 
case that D-serine influences the pharmacokinetics of toluene, specifically by increasing 
the rate of clearance of toluene from the brain. In a study comparing spray painters 
exposed to solvents exhibiting impairments, it was noted that those painters who also 
smoked tobacco had higher toluene clearance from blood than non-smokers, potentially 
due to an enhancement of cytochrome P450 activity in smokers (Smith & Bend, 1981; 
Wallen, 1986).  Importantly, pharmacokinetic models of toluene vapor exposure indicate 
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that alveolar ventilation rate is highly influential in predicting blood toluene 
concentrations in rats (Kenyon et al., 2008).  
Co-agonists glycine and D-serine act to increase the recovery rate from receptor 
desensitization during synaptic activation, and this effect may be the driving force behind 
reductions in the time to recover from the locomotor stimulating and neurological 
impairing effects of acute toluene vapor exposures (Yang & Svensson, 2008). Both 
inhaled toluene exposure concentration and duration have been related to the increase of 
brain and blood toluene concentrations (Kishi, et al., 1988). A large portion of un-
metabolised inhaled toluene (7-14%) is excreted in exhaled air (Lof, et al., 1993). Pre-
treatment of D-serine may act to increase the rate of ventilation and thus increase the 
amount of un-metabolized toluene excreted via respiration. For instance, NMDA 
receptors are responsible for mediating the transition from inspiration to expiration, and 
NMDA receptor blockade by antagonists results in apneusis (a breathing pattern 
characterized by gasping during the inspiration phase and a shortened, insufficient 
expiration phase) (Haji, Okazaki, & Takeda, 2000). Although it is yet to be determined 
whether D-serine affects ventilation directly, it is a probable hypothesis to explain the 
effects noted in the current study.  Future studies should look at how increasing the rate 
of respiration may act to decrease brain/toluene concentrations as this effect would be an 
excellent option for reducing the effects of acute toluene intoxication in clinical settings. 
 
4.4.2. Considerations of the route of toluene administration 
Lo and colleagues found that total distance travelled (cm) following an acute 
toluene injection (750 mg/kg) over a 90 min test phase was significantly attenuated by 
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pre-treatment of D-serine (1000 mg/kg). The current study found that rather than being 
attenuated, the locomotor stimulating effects of toluene were shifted such that latency to 
recover from these impairments was significantly shortened during a 30 min test phase, 
following the highest length of exposure studied here (5000 ppm for 30 min).  When 
analyzed in the current study, total number of line crosses did not significantly differ 
between D-serine and vehicle-injected rats following toluene exposure (results not 
shown) indicating a difference between these results and those of Lo and colleagues. 
Behaviourally speaking the effects of injected and inhaled toluene may differ. Due to the 
ease of dose determination, injection of toluene has been commonly used as a rodent 
model of toluene intoxication, even though this route of administration is essentially 
unheard of in reports of human toluene abuse. Inhaled toluene results in observable 
changes in behaviour sooner than injected toluene (Bowen, et al., 2006). Inhaled and 
injected toluene groups also show a different pattern of c-Fos expression following a 30 
min exposure to 5000 ppm toluene compared to injection of 1000 mg/kg toluene (Chen, 
et al., 2005; Perit, et al., 2012). The mechanism underlying these differences is unknown 
but may be due to overall differences in brain toluene concentrations. Lo and colleagues 
found that a dose of 750 mg/kg toluene resulted in increased locomotion but also ataxia 
and hindlimb abduction (or splaying) indicating that this dose was comparable to the 
behavioural effects of inhaled toluene noted in the current study. There may have been a 
delay in the behavioural effects as timing of behaviour onset was not reported. 
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4.5. Limitations  
A potential limitation to the current study was the timing of injections and the 
dose of D-serine and picrotoxin. It is difficult to compare the behavioural effects of D-
serine and picrotoxin as D-serine was injected 30 min prior to pre-testing and picrotoxin 
was injected 10 min prior. However, each injection time was chosen based on previous 
research. D-serine (1000 mg/kg) injected i.p. 30 min before toluene exposure had 
significant effects on toluene-induced motor and cognitive behaviour (Lo, et al., 2009). It 
was more difficult to choose an injection schedule for picrotoxin as the methodologies of 
the existing studies differ greatly from one study to the next. Although a recent study 
showed that 0.01 and 0.03 mg/kg toluene injected immediately prior to an acute toluene 
exposure attenuated toluene-induced hypothermia, the current study was interested in 
motor behaviours, including locomotion (Paez-Martinez et al., 2013). Therefore the 
current study employed an injection schedule and dose of picrotoxin (0.05 mg/kg, 10 min 
prior to toluene inhalation) based on a study which used the same schedule and found that 
picrotoxin significantly enhanced the locomotor stimulating effects of ethanol (Liljequist 
& Engel, 1982).  
 
4.6. Future Directions 
Based on the outcomes of the current study, a future study exploring the effects of 
D-serine pre-treatment on various toluene vapor exposure durations (ex. 15, 30, 45, 60 
min) could identify a potential dose-dependent response to NMDA receptor drugs.  This 
would potentially allow for the construction of a timeline which could ultimately be used 
to identify the stages of toluene intoxication and the receptors involved.  A second study 
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focusing on the effects of D-serine following an acute toluene exposure would also be 
warranted, as this could ultimately lead to the development of therapeutics to be used in 
clinical settings for patients hospitalized for toluene use. Lastly it will be necessary to 
incorporate measures of rate of respiration in future studies in order to identify whether 
D-serine has an effect on respiration, and whether this effect drives increases in toluene 
clearance. 
 
4.7. Conclusions 
D-serine but not picrotoxin reduced the recovery time from an acute toluene-
vapor exposure. The neurological and locomotor impairments caused by acute toluene 
vapor exposures may therefore more likely be due to changes in NMDA receptor function 
than GABA receptor function. This result adds to the growing body of literature which 
attempts to determine the mechanism of action of toluene vapor in the brain. 
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